This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters (ARTEMIS1)

This study has been terminated.
Sponsor:
Information provided by (Responsible Party):
Proximagen, LLC
ClinicalTrials.gov Identifier:
NCT01390220
First received: July 6, 2011
Last updated: September 19, 2017
Last verified: April 2017
  Purpose
The purpose of this study is to examine the safety and effectiveness of USL261 for the outpatient treatment of seizure clusters.

Condition Intervention Phase
Epilepsy Drug: USL261 Drug: Placebo Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Intranasal Midazolam (USL261) in the Outpatient Treatment of Subjects With Seizure Clusters. ARTEMIS-1: Acute Rescue Therapy in Epilepsy With Midazolam Intranasal Spray-1

Resource links provided by NLM:


Further study details as provided by Proximagen, LLC:

Primary Outcome Measures:
  • Proportion of subjects who meet the criteria for Treatment Success. [ Time Frame: 6 hours ]
    Treatment Success is defined as achieving both of the following: 1) termination of seizure(s) within 10 minutes after study drug administration, and 2) no recurrence of seizure(s) beginning 10 minutes after study drug administration to 6 hours after study drug administration.


Secondary Outcome Measures:
  • Proportion of subjects with recurrence of seizure(s) beginning 10 minutes after study drug administration to 4 hours after study drug administration. [ Time Frame: 4 hours ]
  • Time to next seizure with a start time > 10 minutes after study drug administration. [ Time Frame: 24 hours ]

Enrollment: 201
Study Start Date: June 2011
Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: USL261
5 mg intranasal midazolam
Drug: USL261
Experimental: Placebo
Intranasal placebo
Drug: Placebo

  Eligibility

Ages Eligible for Study:   12 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Has a competent, adult caregiver who can recognize and observe the subject's seizure cluster episodes
  • Has an established diagnosis of partial or generalized epilepsy that includes the following:

    • A documented history of seizure clusters lasting a minimum of 10 minutes
    • Seizure cluster pattern is observable, stereotyped, and recognizably different from the subject's other non-cluster seizure activity (if any)
    • A second seizure in the seizure cluster typically occurring within 6 hours from the time of cluster recognition
    • A seizure cluster pattern composed of multiple (≥ 2) partial or generalized seizures
    • A seizure cluster pattern established > 3 months before Visit 1
    • A frequency of ≥ 3 seizure clusters during the year before Visit 1
    • At least 1 seizure cluster occurring ≤ 4 months before Visit 1
    • Seizure cluster pattern is confirmed by a central reviewer
  • Currently on a stable regimen of AEDs (no changes in type of AEDs) since Visit 1 and for ≥ 7 days before Visit 2, with or without intermittent use of benzodiazepines at a constant dose
  • Weight is 40kg to 125kg, inclusive

Exclusion Criteria:

  • Has a neurological disorder that is likely to progress in the next year
  • Has severe chronic cardio-respiratory disease
  • Has had psychogenic, non-epileptic seizure(s) within the 5 years before Visit 1
  • Has a history of their stereotypical seizure cluster progressing to status epilepticus within the 2 years before Visit 1
  • Has a history of acute narrow-angle glaucoma.
  • Has had active suicidal plan/intent or active suicidal thoughts in the 6 months before Visit 1 or a suicide attempt in the past 5 years
  • Currently using a VNS unless the device has been implanted for at least 6 months and the setting stable for 4 weeks before Visit 1
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01390220

  Hide Study Locations
Locations
United States, Arizona
United States, Arizona
Phoenix, Arizona, United States
United States, Arizona
Scottsdale, Arizona, United States
United States, Arizona
Tucson, Arizona, United States
United States, Arkansas
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
United States, California
Fresno, California, United States
United States, California
Irvine, California, United States
United States, California
Loma Linda, California, United States
United States, California
Los Angeles, California, United States
United States, California
Oxnard, California, United States
United States, California
Sacramento, California, United States
United States, California
San Francisco, California, United States
United States, California
Ventura, California, United States
United States, Colorado
United States, Colorado
Aurora, Colorado, United States
United States, Connecticut
United States, Connecticut
New Haven, Connecticut, United States
United States, Florida
United States, Florida
Altamonte Springs, Florida, United States
United States, Florida
Gainesville, Florida, United States
United States, Florida
Gulf Breeze, Florida, United States
United States, Florida
Loxahatchee Groves, Florida, United States
United States, Florida
Miami, Florida, United States
United States, Florida
Port Charlotte, Florida, United States
United States, Florida
Tampa, Florida, United States
United States, Idaho
United States, Idaho
Boise, Idaho, United States
United States, Illinois
United States, Illinois
Chicago, Illinois, United States
United States, Indiana
United States, Indianapolis
Indianapolis, Indiana, United States
United States, Kansas
United States, Kansas
Manhattan, Kansas, United States
United States, Kentucky
United States, Kentucky
Lexington, Kentucky, United States
United States, Lexington
Lexington, Kentucky, United States
United States, Kentucky
Louisville, Kentucky, United States
United States, Maryland
United States, Maryland
Baltimore, Maryland, United States
United States, Maryland
Bethesda, Maryland, United States
United States, Michigan
United States, Michigan
Detroit, Michigan, United States
United States, Minnesota
United States, Minnesota
Saint Paul, Minnesota, United States
United States, Missouri
United States, Missouri
Chesterfield, Missouri, United States
United States, Missouri
Saint Louis, Missouri, United States
United States, Nevada
United States, Nevada
Reno, Nevada, United States
United States, New Hampshire
United States, New Hampshire
Lebanon, New Hampshire, United States
United States, New Jersey
United States, New Jersey
Camden, New Jersey, United States
United States, New Jersey
Flemington, New Jersey, United States
United States, New Jersey
Gibbsboro, New Jersey, United States
United States, New Jersey
Hackensack, New Jersey, United States
United States, New Jersey
New Brunswick, New Jersey, United States
United States, New York
United States, New York
Albany, New York, United States
United States, New York
Buffalo, New York, United States
United States, New York
East Setauket, New York, United States
United States, New York
New York, New York, United States
United States, New York
The Bronx, New York, United States
United States, North Carolina
United States, North Carolina
Durham, North Carolina, United States
United States, North Carolina
Winston-Salem, North Carolina, United States
United States, Ohio
United States, Ohio
Akron, Ohio, United States
United States, Ohio
Columbus, Ohio, United States
United States, Ohio
Dayton, Ohio, United States
United States, Oklahoma
United States, Oklahoma
Oklahoma City, Oklahoma, United States
United States, Oregon
United States, Oregon
Portland, Oregon, United States
United States, Pennsylvania
United States Pennsylvania
Philadelphia, Pennsylvania, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
United States, Philadelphia
Philadelphia, Pennsylvania, United States
United States, Pennsylvania
Pittsburgh, Pennsylvania, United States
United States, Tennessee
United States, Tennessee
Memphis, Tennessee, United States
United States, Tennessee
Nashville, Tennessee, United States
United States, Texas
United States, Dallas
Dallas, Texas, United States
United States, Texas
Dallas, Texas, United States
United States, Texas
Fort Worth, Texas, United States
United States, Texas
Greenville, Texas, United States
United States, Texas
Houston, Texas, United States
United States, San Antonio
San Antonio, Texas, United States
United States, Texas
San Antonio, Texas, United States
United States, Texas
Temple, Texas, United States
United States, Utah
United States, Utah
Salt Lake City, Utah, United States
United States, Virginia
United States, Virginia
Charlottesville, Virginia, United States
United States, Virginia
Norfolk, Virginia, United States
United States, Virginia
Richmond, Virginia, United States
United States, Virginia
Virginia Beach, Virginia, United States
United States, Wisconsin
United States, Wisconsin
Madison, Wisconsin, United States
United States, Wisconsin
Marshfield, Wisconsin, United States
Australia, New South Wales
Australia, New South Wales
Chatswood, New South Wales, Australia
Australia, New South Wales
Randwick, New South Wales, Australia
Australia, New South Wales
Westmead, New South Wales, Australia
Australia, Victoria
Australia, Victoria
Fitzroy, Victoria, Australia
Australia, Vctoria
Heidelberg West, Victoria, Australia
Australia, Victoria
Parkville, Victoria, Australia
Canada, Ontario
Canada, Ontario
Toronto, Ontario, Canada
Canada, Quebec
Canada, Quebec
Montreal, Quebec, Canada
Germany
Germany, Ulm
Ulm, Baden Wurttemberg, Germany
Germany, Baden-Wurttemberg
Freiburg, Baden-Wurttemberg, Germany
Germany, Bayern
Erlangen, Bayern, Germany
Germany, Bayern
Munich, Bayern, Germany
Germany, Hessen
Marburg, Hessen, Germany
Germany, Nordrhein-Westfalen
Bonn, Nordrhein-Westfalen, Germany
Germany, Westfalen-Lippe
Bielefeld, Wetsfalen-Lippe, Germany
Hungary
Hungary, Budapest
Budapest, Hungary
Hungary
Budapest, Hungary
Hungary
Kazincbarcika, Hungary
Hungary
Miskolc, Hungary
Hungary
Nyiregyhaza, Hungary
Hungary
Pecs, Hungary
Israel
Israel
Haifa, Israel
Israel
Holon, Israel
Israel
Jerusalem, Israel
Israel, Tikva
Petach Tikva, Israel
Israel
Ramat Gan, Israel
Israel
Tel Aviv, Israel
Italy
Italy, Lombardy
Pavia, Lombardy, Italy
Italy
Bari, Italy
Italy
Firenze, Italy
Italy
Genova, Italy
Italy
Milano, Italy
Italy
Napoli, Italy
Italy
San Fermo della Battaglia, Italy
New Zealand
New Zealand, Auklund
Grafton, Auklund, New Zealand
New Zealand, Canterbury
Christchurch, Canterbury, New Zealand
New Zealand, Waikato
Hamilton, Waikato, New Zealand
Poland
Poland,Warmian-Masurian Voivodeship
Olsztyn, Warmian-Masurian Voivodeship, Poland
Poland
Gdansk, Poland
Poland
Katowice-Ochojec, Poland
Poland, Krakow
Krakow, Poland
Poland
Krakow, Poland
Poland
Lubin, Poland
Spain
Spain, Andalucia
Sevilla, Andalucia, Spain
Spain, Catalonia
Girona, Catalonia, Spain
Spain, Catalonia
Terrassa, Catalonia, Spain
Spain, Madrid
Aravaca, Madrid, Spain
Spain, Madrid
Mirasierra, Madrid, Spain
Spain, Madrid
Pozuelo de Alarcon, Madrid, Spain
Spain, Madrid
Madrid, Spain
Ukraine
Ukraine, Uzhgorod
Uzhgorod, Zakarpattia, Ukraine
Ukraine, Ivano-Frankivsk
Ivano-Frankivsk, Ukraine
Ukraine, Kharkiv
Kharkiv, Ukraine
Ukraine, Lviv
Lviv, Ukraine
Ukraine, Odessa
Odessa, Ukraine
Ukraine, Poltava
Poltava, Ukraine
Ukraine, Ternopil
Ternopil, Ukraine
Ukraine, Vinnytsya
Vinnytsya, Ukraine
Ukraine, Zaporizhzhya
Zaporizhzhya, Ukraine
Sponsors and Collaborators
Proximagen, LLC
  More Information

Responsible Party: Proximagen, LLC
ClinicalTrials.gov Identifier: NCT01390220     History of Changes
Other Study ID Numbers: P261-401
2011-001318-32 ( EudraCT Number )
Study First Received: July 6, 2011
Last Updated: September 19, 2017

Keywords provided by Proximagen, LLC:
Epilepsy
seizure clusters
acute repetitive seizures
rescue treatment
ARTEMIS

Additional relevant MeSH terms:
Epilepsy
Seizures
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Midazolam
Adjuvants, Anesthesia
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 25, 2017